<DOC>
	<DOCNO>NCT02370589</DOCNO>
	<brief_summary>This randomize , observer-blind , placebo-controlled trial male female subject ≥18 &lt; 50 year age . Subjects healthy adult base history , physical examination , baseline clinical laboratory test . Approximately 230 eligible subject enrol 1 13 treatment group . Treatments comprise two IM dose 21-day interval ( Day 0 Day 21 ) , alternate deltoid test article assign ( i.e. , saline placebo , dose EBOV GP vaccine without Matrix-M adjuvant ) , 0.5mL injection volume .</brief_summary>
	<brief_title>Study Evaluate Immunogenicity Safety Ebola Virus ( EBOV ) Glycoprotein ( GP ) Vaccine Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhagic Fever , Ebola</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<criteria>1 . Healthy adult male female , ≥18 year age , upper limitation &lt; 50 year . 2 . Willing able give inform consent prior study enrollment , 3 . Able comply study requirement , 4 . Women childbearing potential must negative urine pregnancy test prior vaccination , advise Informed Consent process avoid become pregnant duration study , must assert employ effective form birth control duration study . Acceptable form birth control : credible history continuous abstinence heterosexual activity prior surgical sterilization , hormonal contraceptive ( oral , injectable , implant , patch , ring ) , barrier contraceptive ( condom diaphragm ) , intrauterine device ( IUD ) . Women adequately document history surgical sterility exempt urine pregnancy test . 1 . Any ongoing , symptomatic acute chronic illness require medical surgical care . Asymptomatic condition finding ( e.g . mild hypertension , dyslipidemia ) associate evidence endorgan damage exclusionary provide appropriately manage clinically stable ( i.e. , unlikely result symptomatic illness within timecourse study ) opinion investigator . Note illness condition may exclusionary , even otherwise stable , due therapy use treat ( see exclusion criterion 2 , 5 , 7 , 8 , 9 ) . 2 . Participation research involve investigational product ( drug/biologic/device ) within 45 day plan date first vaccination . 3 . History serious reaction prior vaccination . 4 . Any occupational exposure Ebolaviruses recovery past Ebolavirus disease . 5 . Received vaccine 4 week precede study vaccination ; Ebolavirus vaccine time . 6 . Any known suspected immunosuppressive condition , acquire congenital , determined history and/or physical examination . 7 . Chronic administration ( define 14 continuous day ) immunosuppressant immunemodifying drug within 6 month prior administration study vaccine . An immunosuppressive dose glucocorticoid define systemic dose ≥10 mg prednisone per day equivalent . The use topical nasal glucocorticoid permit . Inhaled glucocorticoid ≥500µg per day beclamethasone fluticasone , 800μg per day budesonide exclusionary . 8 . Administration immunoglobulins and/or blood product within 3 month precede administration study vaccine study . 9 . Acute disease time enrollment ( define presence moderate severe illness without fever , oral temperature &gt; 38.0°C planned day vaccine administration ) . 10 . Known disturbance coagulation . The use ≤325mg aspirin per day prophylaxis permit , use platelet aggregation inhibitor , thrombin inhibitor , factor Xa inhibitor , warfarin derivative exclusionary , regardless bleed history , imply treatment prophylaxis know cardiac vascular disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Ebola</keyword>
</DOC>